Protocol D - splenomegaly

Type:
Prevalence / cross-sectional
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Uganda
Partners:
Medical Research Council (MRC-Masaka)-Masaka, Uganda

Study Summary:
To characterize the effect splenomegaly may have on clinical laboratory reference ranges among adults to determine relevant inclusion and exclusion criteria and to interpret safety data for HIV vaccine trials at a research center where the prevalence of splenomegaly is high.

Protocol A

Type:
Prevalence / cross-sectional
Study Status:
Completed
Enrollment Status:
Completed
Countries:
Uganda;Kenya
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Medical Research Council (MRC-Masaka)-Masaka, Uganda; Kakira-JCRC, Uganda.

Study Summary:
To estimate the number of individuals not infected with HIV who are available for a preventive HIV vaccine trial by measuring the prevalence of HIV infection in individuals who volunteer for this study.

Protocol D

Type:
Prevalence / cross-sectional
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Kenya;Uganda;Rwanda;Zambia
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)- Entebbe, Uganda; Medical Research Council (MRC-Masaka)-Masaka, Uganda; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia.

Study Summary:
To establish clinical laboratory reference ranges among adults to determine relevant inclusion and exclusion criteria and to interpret safety data for HIV vaccine trials in the context of medical conditions present in an asymptomatic adult population at multiple sites in Africa.

Protocol E

Type:
Prevalence / cross-sectional
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Kenya;Rwanda
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda.

Study Summary:
To characterise immune responses to HIV vaccine encoded proteins in HIV infected individuals and assess cryopreservation of Peripheral Blood Mononuclear cells in preparation for preventive vaccine studies